Nashville, TNNCT07225543Now EnrollingIRB Ready

Systemic Lupus Erthematosus (SLE) Clinical Trial in Nashville, TN

Access cutting-edge systemic lupus erthematosus (sle) treatment through this clinical trial at a research site in Nashville. Study-provided care at no cost to qualified participants.

Sponsored by Vanderbilt University Medical Center

Quick Self-Assessment

See if you qualify for this Nashville location

Preparing your pre-screening questions…

Expert Care in Nashville

Access systemic lupus erthematosus (sle) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related systemic lupus erthematosus (sle) treatment provided free

Apply for This Nashville Location

Check if you qualify for this systemic lupus erthematosus (sle) clinical trial in Nashville, TN

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Nashville

    Convenient for TN residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Nashville site if eligible
  4. 4Begin participation

About This Systemic Lupus Erthematosus (SLE) Study in Nashville

This is a phase II randomized, placebo-controlled, double-blind, cross-over study to determine the effect of isolevuglandin (IsoLG) scavenging by 2-HOBA on blood pressure and immune activation in patients with SLE. 42 patients with stable SLE will be randomized to treatment sequence to receive placebo or 500mg 2-HOBA three times a day for 8 weeks followed by a 4 week washout and then 8 weeks of the other agent. Primary outcome measures include change in 24-hour blood pressure and NETosis. This study will provide mechanistic information on the role of IsoLGs in autoimmune disease-associated hypertension and immune activation.

Sponsor: Vanderbilt University Medical Center

Who Can Participate

Inclusion Criteria

Written informed consent
Age ≥18 years
Female (biological)
Meeting the 2019 European League Against Rheumatism/ American College of Rheumatology classification criteria for SLE32
No change in immunosuppressants ≥3 months
Stable prednisone (or equivalent) dose ≤ 20mg/ day for ≥ 1 month
Elevated blood pressure defined as \>120 and \< or = 160 mmHg systolic or \>80 and \< or = 110 mmHg diastolic blood pressure at screening visit
No change in anti-hypertensive dose ≥2 weeks
Willingness to stop NSAIDs for ≥2 weeks before and throughout the study
If of childbearing potential, willingness to use effective birth control throughout the study and 4 weeks after completion of the study (examples: condom, diaphragm, oral contraceptive pill, intrauterine device)

Exclusion Criteria

Pregnant or breastfeeding
Male (biological)
Active cancer except for non-melanoma skin cancer
Prior diagnosis of liver cirrhosis or the following abnormal liver function studies: AST or ALT \>1.5x the upper limit of normal or total bilirubin ≥1.5 mg/dl
Active infection requiring medical intervention
Major surgery in ≤ 3 months
Aspirin allergy
Use of MAO-I
Estimated creatinine clearance \<30 ml/min
Known atrial fibrillation
Severe comorbid condition

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Nashville?

Yes, this clinical trial (NCT07225543) has an active research site in Nashville, TN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Systemic Lupus Erthematosus (SLE) Treatment Options in Nashville, TN

If you're searching for systemic lupus erthematosus (sle) treatment options in Nashville, TN, this clinical trial (NCT07225543) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Nashville research site is actively enrolling participants for this clinical trial. You'll receive care from experienced systemic lupus erthematosus (sle) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all systemic lupus erthematosus (sle) clinical trials near you to find additional studies recruiting in your area.

More Heart Attack Trials in Nashville, TN

See all heart attack clinical trials recruiting in Nashville — not just this study.

Browse Heart Attack Trials in Nashville →

Browse More Trials by Condition

Heart Attack TrialsLupus TrialsInterstitial Cystitis TrialsSystemic Lupus Erythematosus TrialsMyocardial Infarction TrialsAll Conditions →

Ready to Join in Nashville?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Nashville, TN